tbuckley/cabot-search huggingface dataset:
AB0747 Psoriatic Arthritis Registry of Turkey (PSART): Results of A Multicenter Registry on 1081 Patients:
Authors: S.Z. Aydin, O. Bayindir, M.F. Oksuz, A. Dogru, G. Kimyon, E.F. Tarhan, A. Erden, S. Yavuz, M. Can, G.Y. Cetin, L. Kilic, O. Kucuksahin, A. Omma, C. Ozisler, D. Solmaz, A.M. Onat, B. Kisacik, D.E. Ersozlu Bozkirli, M.A. Tufan, L. Akyol, M. Cinar, S.M. Pehlevan, A. Tufan, F. Yildiz, A. Balkarli, F. Erbasan, R. Mercan, E.K. Gunal, F. Arslan, T. Kasifoglu, S. Senel, S. Kobak, B. Yilmazer, S. Yilmaz, T.M. Duruoz, A. Kucuk, E.O. Gonullu, K. Aksu, Y. Kabasakal, M. Sahin, N. Cakir, S. Erten, M. Sayarlioglu, E. Dalkilic, S. Akar, C. Acikel, N. Atakan, U. Kalyoncu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> PsART (PsA registry of Turkey) is a multicenter web-based registry. <h3>Objectives</h3> The objective of this registry is to assess characteristics of PsA and compare the differences among genders in our population. <h3>Methods</h3> PsART was established in 2014 including 32 rheumatology centers. Detailed data regarding demographics for the skin and joint disease, disease activity assessments and treatment choices were collected. <h3>Results</h3> One thousand and eighty-one patients (64.7% women) with a median (range) PsA duration for 3.7 (0–45) years were enrolled. Median psoriasis duration was 13 (0–59) years. The most frequent type of PsA was polyarticular 437 (40.5%) followed by oligoarticular 407 (37.7%) and axial disease 372 (34.4%). Patients with a combination of axial and peripheral disease had a longer disease duration than patients with one type of joint disease (52 (0–545) vs 42 (0–486) months, p=0.008). Mean (SD) swollen and tender joint counts were 1.7 (3) and 3.6 (4.8). 38.6% of patients were on csDMARD monotherapy, 7.1% were anti-TNF monotherapy and 22.5% were using anti-TNF plus csDMARD combinations. Within items included in the minimal disease activity, only 17.6%&gt;67% of patients had inactive disease state. The major differences among genders were women being older (48.3 (12.8) VS 44.4 (12.5), P&lt;0.001), more fatigue and higher HAQ scores (Table). Women also had more frequent peripheral arthritis than men and less axial disease (only peripheral vs axial vs combined, n (%): women: 479 (68.5%), 62 (8.9%), 158 (22.6%) respectively; men: 222 (59.4%), 41 (11%), 111 (29.7%) respectively; p=0.011). Women had significantly more history of psoriasis in their family compared to men (34.8% vs 25.7%, p=0.003). <h3>Conclusions</h3> PsART had similarities with the previously published registries, supporting its external validity. Women having more fatigue and worse functioning and as well as the high percentage of active disease state point out to the unmet need in treatment of PsA. <h3>Disclosure of Interest</h3> None declared
Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Authors: Stefan Faderl, Varsha Gandhi, Srdan Verstovsek, Jorge Cortes, Farhad Ravandi-Kashani, Miloslav Beran, Guillermo Garcia-Manero, Charles Koller, Susan O’Brien, Alessandra Ferrajoli, Zeev Estrov, Monica Kwari, William Plunkett, Hagop M. Kantarjian
Journal: Blood (2004)
Efficacy of Allogeneic Stem-Cell Transplantation for T/NK-Cell Lymphomas in Adults.
Authors: Steven Le Gouill, Noel-Jean Milpied, Agnes Buzyn, Regis Peffault de la Tour, Jean-Paul Vernant, Mohamad Mothy, Norbert Ifrah, Krimo Bouabdallah, Claude-Eric Bulabois, Jehan Dupuis, Bernard Rio, Michel Attal, Ibrahim Yakoub-Aga, Olivier Tournilhac, Nicole Gratecos, Didier Blaise, Christelle Volteau, Mauricette Michallet
Journal: Blood (2007)
Combination Immunotherapy of Advanced Lymphoma with Oncolytic Vaccinia Virus and Checkpoint Inhibitor Following Local Tumor Irradiation
Authors: Boris Minev, Holbrook Kohrt, Mehmet Kilinc, Nanhai Chen, Audrey Feng, Maysam Pessian, Ulrike Geissinger, Erik Haefner, Desislava Tsoneva, Kliment Bozhilov, Idit Sagiv Barfi, Xing Zhao, Narendiran Rajasekaran, Ronald Levy, Aladar Szalay
Journal: Blood (2014)
Clinical Outcome of Aspergillus-Specific Cytotoxic T Lymphocytes for Refractory Invasive Aspergillosis in Patients with Hematological Malignancies.
Authors: Tong Wu, Chun-Rong Tong, Xing-Yu Cao, Jing-Bo Wang, Lung-Ji Chang, Yin Liang, Dao-Pei Lu
Journal: Blood (2008)
The expression of E-selectin, P-selectin and ICAM-1 in the peritoneal microvessels of portal hypertensive and cirrhotic rats treated with or without peginterferon-alpha2a
Authors: E Vanheule, Am Geerts, H Reynaert, Hans Van Vlierberghe, A Geerts, Martine De Vos, I Colle
Journal: Hepatology (2005)
IL6‐mediated inflammatory loop reprograms normal to epithelial‐mesenchymal transition+ metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta–deficient β2‐spectrin+/− mice
Authors: Abhisek Mitra, Jun Yan, Xueqing Xia, Shouhao Zhou, Jian Chen, Lopa Mishra, Shulin Li
Journal: Hepatology (2016)

Hepatocellular carcinoma (HCC) is the second‐leading cause of cancer‐related deaths worldwide with a poor survival rate. As many as 40% of HCCs are clonal, with alteration of key tumor‐suppressor pathways in stem cells as the primary cause of HCC initiation. However, mechanisms that generate metastatic stem cells in preneoplastic liver tissue are not well understood. We hypothesized that chronic inflammation is a major driver of the transformation of genetically defective liver stem cells (LSCs) into highly metastatic liver cancer cells in premalignant liver tissue. We developed models of chronic inflammation in wild‐type (WT) and β2‐spectrin (β2SP) +/− (SPTBN1) mice. CD133 + LSCs derived from preneoplastic livers of β2SP +/− mice treated with interleukin‐6 (pIL6; IL6 β2SP +/− LSCs) were highly tumorigenic and metastatic, whereas those derived from WT mice treated with pIL6 ( IL6 WT LSCs) had significantly less proliferation and no tumorigenic properties. IL6 β2SP +/− LSCs not only exhibited nuclear localization of Twist and Slug, markers of epithelial‐mesenchymal transition (EMT), but also constitutive activation of nuclear factor kappa B (NFκB; RELA). Knockdown of NFκB decreased the EMT phenotypes and metastatic capacity of these cells. NFκB in IL6 β2SP +/− LSCs was activated by transforming growth factor β (TGFβ)‐activated kinase 1 (TAK1; MAP3K7), which is associated with poor survival in HCC and interleukin‐6 (IL6) expression. The amount of constitutively activated NFκB increased dramatically from normal to cirrhotic to HCC tissues from human patients. Conclusion : IL6‐mediated inflammation programs constitutive activation of the TAK1‐NFκB signaling cascade in CD133 + LSCs, and this program interacts with deficient TGFβ signaling, thereby accelerating the transformation of normal LSCs to metastatic cancer stem cells (mCSCs). Indeed, this study delineates the development of EMT‐positive mCSCs in HCC‐free liver tissue upon chronic inflammation. (H epatology 2017;65:1222‐1236).
Quantification by Superconducting Quantum Interference Device (SQUID) of Iron Overload after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Alessandro Busca, Michele Falda, Paola Manzini, Sergio D’antico, Franco Locatelli, Annalisa Chiappella, Stefano D’Ardia, Filomena Longo, Roberto Calabrese, Antonio Piga
Journal: Blood (2008)
Combined Pharmacologic Inhibition of Bcl-Xl/Bcl-2 and mTORC1/2 Survival Signals Trigger Apoptosis in BCR-ABL1+in Vitro Models of Blast Crisis Chronic Myelogenous Leukemia (CML-BC), and Primary CD34+/CD38− Stem and CD34+ progenitor Cells From CML-BC Patients
Authors: Jason G Harb, Paolo Neviani, Claudia S Huettner, Guido Marcucci, Danilo Perrotti
Journal: Blood (2011)
AB0725 Anti-Tnf-α Therapy Improves Endothelial Function and Arterial Stiffness in Patients with Moderate-To-Severe Psoriasis: A 6-Month Prospective Study
Authors: C. Fernández-Díaz, T. Pina, A. Corrales, R. Lόpez-Mejías, S. Armesto, M.A. González-Lόpez, I. Gόmez-Acebo, B. Ubilla, S. Remuzgo-Martínez, C. González-Vela, R. Blanco, J.L. Hernández, J. Llorca, J. Loricera, M.Ά. González-Gay
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The risk of CV events is closely related to the severity of the psoriasis. The presence of severe psoriasis confers an additional 6.2% absolute risk of a 10-year rate of CV events compared with the general population. Studies on anti-TNF-α therapy indicate that these agents yield a reduction in the incidence of CV events in patients with psoriasis. <h3>Objectives</h3> To determine if the use of the anti-TNF-α monoclonal antibody adalimumab could improve endothelial function and arterial stiffness in patients with moderate-to-severe psoriasis. <h3>Methods</h3> Prospective study on a series of consecutive patients with moderate-to-severe psoriasis who completed 6 months of therapy with adalimumab. Patients with history of cardiovascular events, diabetes mellitus, kidney disease, hypertension or body mass index ≥35 kg/m<sup>2</sup> were excluded. Assessment of endothelial function by brachial artery reactivity measuring flow-mediated endothelial dependent vasodilatation (FMD%), and carotid arterial stiffness by pulse wave velocity (PWV) was performed at the onset of treatment (time 0) and at month 6. <h3>Results</h3> 29 patients were studied. Anti-TNF-α adalimumab therapy yielded a significant improvement of endothelial function. The mean±standard deviation (SD) FMD% values increased from 6.19±2.44% at the onset of adalimumab to 7.46±2.43% after six months of treatment with this biologic agent (p=0.008). Likewise, following the use of adalimumab, PWV levels decreased from 6.28±1.04 m/s at the onset of adalimumab to 5.69±1.31 m/s at 6 months (p=0.03). <h3>Conclusions</h3> Patients with moderate-to-severe psoriasis exhibit improvement of endothelial function and arterial stiffness following anti-TNF-α therapy. These findings are of potential relevance due to increased risk of cardiovascular disease in patients with severe psoriasis. <h3>Acknowledgement</h3> The study was supported by a research grant from Abbvie Inc. <h3>Disclosure of Interest</h3> None declared
Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care
Authors: Suzanne Kamel-Reid, Mariam Thomas, Mahadeo A. Sukhai, Dwayne L. Barber, Swati Garg, Maksym Misyura, Roozbeh Dolatshahi, Djamel Harbi, Tong Zhang, Anna Porwit, Jan M.A. Delabie, Narmin Ibrahimova, Mohamed Shanavas, Karen W.L. Yee, Trevor J. Pugh, Philippe Bedard, Aaron D. Schimmer, Tracy L. Stockley, Vikas Gupta, Mark D. Minden, Andre C Schuh
Journal: Blood (2015)
Comparison of Clinical Outcome Between Children with Aplastic Anemia and Refractory Cytopenia of Childhood Who Received Immunosuppressive Therapy with Antithymocyte Globulin and Cyclosporine
Authors: Asahito Hama, Hideki Muramatsu, Masafumi Ito, Masahiro Tsuchida, Hirotoshi Sakaguchi, Sayoko Doisaki, Makito Tanaka, Akira Shimada, Yoshiyuki Takahashi, Ryoji Kobayashi, Etsuro Ito, Hiromasa Yabe, Shouichi Ohga, Akira Ohara, Seiji Kojima
Journal: Blood (2011)
Targeting Mutant Nucleophosmin 1 (NPM1) Induces Differentiation, Loss of Survival and Sensitizes AML Cells to All-Trans Retinoic Acid, Cytarbine and FLT3 Antagonists
Authors: Ramesh Balusu, Josiah Cox, Stacey Hembruff, Warren Fiskus, Rekha Rao, Uma Mudunuru, Ruben Reyes, Siddhartha Ganguly, Sunil Abhyankar, Heather Male, Allan Fleming, Casey B Williams, Joseph McGuirk, Kapil N. Bhalla
Journal: Blood (2011)
Graft-Versus-Tumor Effects after Allogeneic Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies.
Authors: Eiji Usui, Takahiro Fukuda, Ruri Kato, Satoshi Yamasaki, Dai Maruyama, Yuriko Morita, Sung-Won Kim, Shin-ichiro Mori, Ryuji Tanosaki, Kinuko Tajima, Yuji Heike, Atsushi Makimoto, Kensei Tobinai, Yoichi Takaue
Journal: Blood (2005)
AB0757 Clinically Important Improvement Thresholds for Harris Hip Score and Its Ability To Predict Revision Risk after Primary Total Hip Arthroplasty
Authors: J.A. Singh, C. Schelck, S. Harmsen, D.G. Lewallen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Harris Hip Score (HHS) is the most commonly used instrument in the assessment of total hip arthroplasty (THA). Clinically meaningful thresholds for HHS have not been defined; limited data exist on responsiveness. <h3>Objectives</h3> To examine the clinically meaningful change thresholds, responsiveness and predictive ability of the Harris Hip Score (HHS) questionnaire. <h3>Methods</h3> We included a cohort of patients who underwent primary total hip arthroplasty (THA) and responded to HHS preoperatively and/or at 2- or 5-year post-THA to examine the clinically meaningful change thresholds (Minimal clinically important improvement, MCII; and moderate improvement), responsiveness (effect size (ES) and standardized response mean (SRM)) based on pre- to post-operative change and its predictive ability at 2- and 5-years post-THA for future revision. <h3>Results</h3> 2,667 patients with mean age of 64 years completed baseline HHS; 1,036 completed both baseline and 2-year and 669 both baseline and 5-year HHS. MCII and moderate improvement thresholds ranged 15.9–18 points and 39.6–40.1 points, respectively. ES was 3.12 and 3.02 at 2- and 5-years; respective SRM was 2.73 and 2.52. Compared to patients with HHS scores of 81–100 (score range, 0–100), patients with scores &lt;55 at 2- and 5-years had higher hazards (95% confidence interval) of subsequent revision, 4.34 (2.14, 7.95; p&lt;0.001) and 3.08 (1.45, 5.84; p=0.002), respectively. Compared to HHS score improvement &gt;50 points from preoperative to 2-years post-THA, lack of improvement/worsening or 1–20 point improvement were associated with increased hazards of revision, 18.10 (1.41, 234.83; p=0.02); and 6.21 (0.81, 60.73; p=0.10), respectively. <h3>Conclusions</h3> HHS is a valid measure of THA outcomes, is responsive to change and predictive of revision risk post-primary THA. We have defined MCID and moderate improvement thresholds for HHS in this study. <h3>References</h3> None <h3>Acknowledgement</h3> We thank Youlonda Lochler for assisting data extraction from the Mayo Clinic Total Joint Registry. <h3>Disclosure of Interest</h3> J. Singh Grant/research support from: Savient, Takeda, Consultant for: Savient, Takeda, Regeneron, Iroko, Merz, Bioiberica, Crealta, and Allergan pharmaceuticals, C. Schelck: None declared, S. Harmsen: None declared, D. Lewallen Shareholder of: pipeline, Grant/research support from: DePuy, Stryker, Biomet and Zimmer, Consultant for: Zimmer, Orthosonic and Osteotech
360O Clinicopathological and functional analyses of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors
Authors: Y. Suehara, M. Ishii, K. Akaike, K. Mukaihara, D. Kubota, T. Okubo, T. Yao, K. Kaneko, T. Saito
Journal: Annals of Oncology (2015)
A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins
Authors: Senko Tsukuda, Koichi Watashi, Taichi Hojima, Masanori Isogawa, Masashi Iwamoto, Katsumi Omagari, Ryosuke Suzuki, Hideki Aizaki, Soichi Kojima, Masaya Sugiyama, Akiko Saito, Yasuhito Tanaka, Masashi Mizokami, Camille Sureau, Takaji Wakita
Journal: Hepatology (2016)

Introduction of direct‐acting antivirals against hepatitis C virus (HCV) has provided a revolutionary improvement in the treatment outcome. In contrast to HCV, however, the strategy for developing new antiviral agents against hepatitis B virus (HBV), especially viral‐targeting compounds, is limited because HBV requires only four viral genes for its efficient replication/infection. Here, we identify an oligomeric flavonoid, proanthocyanidin (PAC) and its analogs, which inhibit HBV entry into host cells by targeting the HBV large surface protein (LHBs). Through cell‐based chemical screening, PAC was identified to inhibit HBV infection with little cytotoxic effect. PAC prevented the attachment of the preS1 region in the LHBs to its cellular receptor, sodium taurocholate cotransporting polypeptide (NTCP). PAC was shown to target HBV particles and impair their infectivity, whereas it did not affect the NTCP‐mediated bile acid transport activity. Chemical biological techniques demonstrated that PAC directly interacted with the region essential for receptor binding in the preS1 region in the LHBs protein. Importantly, PAC had a pan‐genotypic anti‐HBV activity and was also effective against a clinically relevant nucleoside analog‐resistant HBV isolate. We further showed that PAC augmented the ability of a nucleoside analog, tenofovir, to interrupt HBV spread over time in primary human hepatocytes by cotreatment. Moreover, derivative analysis could identify small molecules that demonstrated more‐potent anti‐HBV activity over PAC. Conclusion : PAC and its analogs represent a new class of anti‐HBV agents that directly target the preS1 region of the HBV large surface protein. These agents could contribute to the development of a potent, well‐tolerated, and broadly active inhibitor of HBV infection. (H epatology 2017;65:1104‐1116).
OC-023 Randomised Trial: The Nutriceutical Zinc Carnosine Works with Bovine Colostrum in Truncating Heavy Exercise Induced Increase in Gut Permeability through Actions on Tight Junctions, Apoptosis and Heat Shock Protein 70 Production
Authors: R Playford, G Davison, T Marchbank, D March, R Thatcher
Journal: Gut (2016)

<h3>Introduction</h3> Heavy exercise causes gut symptoms and, in extreme cases, “heat stroke” due to increased intestinal permeability of luminal toxins. We examined whether zinc carnosine (ZnC) a health food product taken alone or in combination with bovine colostrum, a natural source of growth factors, moderated such effects. <h3>Methods</h3> 8 volunteers completed a four-arm double-blind, placebo-controlled, crossover protocol (14 days placebo, ZnC, colostrum, ZnC + colostrum) prior to standardised exercise undertaken 2 and 14 days after starting treatment. Changes in epithelial resistance, apoptosis signalling molecules and tight junction protein phosphorylation in response to 2<sup>0</sup> C rise were determined using Caco-2 &amp; HT29 intestinal cells. <h3>Results</h3> Body temperature increased 2<sup>0</sup> C and gut permeability (5 h urinary lactulose:rhamnose ratios) increased 3 fold following exercise (0.32 ± 0.016 baseline to 1.0 ± 0.017 at +14 days, <i>p</i> &lt; 0.01). ZnC or colostrum truncated rise by 70% after 14 days treatment. Combination treatment gave additional benefit and truncated exercise induced increase at +2 day (30% reduction, p &lt; 0.01) 2°C temperature rise in <i>in vitro</i> studies caused doubling of apoptosis and reduced epithelial resistance 3–4 fold. ZnC or colostrum truncated these effects (35–50%) with greatest response seen with combination treatment (all p &lt; 0.01). Mechanisms of action included increasing HSP70 and truncating temperature-induced changes in Baxα and Bcl-2. ZnC also increased total occludin and reduced pTyr-claudin, pTyr-occludin and pSer-occludin, enhancing tight junction formation and stabilisation. <h3>Conclusion</h3> ZnC taken alone or with colostrum increased epithelial resistance and tight junction structure and may have value for athletes and preventing heat stroke in military personnel. <h3>Disclosure of Interest</h3> None Declared
Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in Multiple Myeloma: MM016 Trial.
Authors: Nizar J. Bahlis, Adnan Mansoor, Johannes C. Lategan, Karen Valentine, Tedd Thaell, Walter Blahey, Mary Lynn Savoie, Kim Blaikie, Leanne Kmet, Birgitte Roland, Douglas A. Stewart
Journal: Blood (2006)
KIR/HLA-I Mismatching Predicts Risk of Relapse in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Elisa Scquizzato, Renato Zambello, Ilenia Baesso, Stefania Varotto, Maria Paola Albergoni, Antonella Teramo, Elisa Boscaro, Simone Cesaro, Marta Pillon, Elisabetta Calore, Maria Vittoria Gazzola, Gianpietro Semenzato, Chiara Messina, Livio Trentin
Journal: Blood (2008)
Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated
Authors: Heinz Ludwig, Hedwig Kasparu, Richard Greil, Clemens Leitgeb, Ercan Müldür, Elisabeth Rauch, Niklas Zojer, Eva Maria Autzinger, Werner Linkesch, Thomas Kuhr, Ludek Pour, Zdenek Adam
Journal: Blood (2012)
AB0926 Increased Circulating Interleukin-23 in Patients with Sarcoidosis
Authors: S. Kobak, M. Akyildiz, A. Gokduman, T. Atabay, H. Vural
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Sarcoidosis is Th1-mediated chronic granulomatous disease characterized by non-caseating granulomas formation. Interleukin-23 (IL-23) is a protein encoded by the IL-23 gene in humans and is produced by dendritic cells and macrophages. IL-23 and IL-12 share a common p40 subunit and are important proinflammatory cytokines. <h3>Objectives</h3> This study aim to determine the serum IL-23 level as well as serum IL-6, IL-12, IL-17 levels in patients with sarcoidosis, and to determine a possible correlation with clinical and laboratory findings of the disease. <h3>Methods</h3> Forty-four biopsy proven sarcoidosis patients followed at a single center and 41 healthy volunteers were included in the study. Demographic, clinical, laboratory and radiological data of all patients were recorded. Serum samples from all the patients and the control group were taken and IL-6, IL-12, IL-17, IL-23 were measured by ELISA method. <h3>Results</h3> Among 44sarcoidosis patients 13 (29.5%) were male and 31 (70.5%) were female. Average patient age was 47.4 years, mean disease duration was 3.2year. Twenty-one (47.7%) patients had erythema nodosum, three (6.8%) had uveitis, 40 (90.9%) had arthralgia, 23 (52.3%) had ankle arthritis, 15 (34.1%) had enthesitis. Laboratory evaluation showed increased serum ACE level in 24 (54.5%) patients, increased serum calcium level in 11 (25%) patients, increased serum D3 level in 5 (11.4%) patients, increased ESR and CRP levels in 22 (50%) and 23 (52.3%) patients, respectively. Compared with the control group higher serum IL-23 level were found in patients with sarcoidosis (p=0.01). Serum IL-23 were associated with ankle arthritis (p=0.02). Serum IL-6, IL-12 and IL-17 levels were similar in sarcoidosis patients and control group (p=0.128, p=0.212, p=0.521 respectively). <h3>Conclusions</h3> In our study we found increased serum IL-23 in patients with sarcoidosis, while serum IL-6, IL-12 and IL-17 were detected as normal. Despite our results are somewhat contradictory to other studies in literature, sarcoidosis still should be discussed if is Th1/Th17 disease or not? Multicenter studies are needed in this regard. <h3>Disclosure of Interest</h3> None declared
Concerns with novel concussion protocol
Authors: David Wyndham Lawrence, MichaelG Hutchison
Journal: British Journal of Sports Medicine (2016)

We read with interest a recent article by Fremont1 presenting a novel approach to the management of athletes with a suspected concussion in which he questions the need for every athlete with a suspected concussion to undergo medical consultation with a physician. We commend Fremont's recognition of the significance and burden of this injury and his development of a novel scheme that would reduce the demands placed on the healthcare system; however, we have identified a number of challenges and concerns that would limit its applicability.

We challenge the underlying assumption …